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a Case of Influenza a (H3N2) 
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season
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With multiple available vaccines and antivirals, seasonal influenza A is typically a self-lim-
ited acutely debilitating illness in young healthy adults. Here, we illustrate unexpected 
morbidity and mortality in a relatively young and healthy patient seen at a large tertiary 
care academic medical center for seasonal influenza A (H3N2) complicated by commu-
nity-acquired pneumonia, hypoxic respiratory failure, septic shock, and death.
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BaCKGRoUND
Seasonal influenza remains a major public health concern given its association with increased 
morbidity and mortality in certain high-risk populations. Recent modeling by the Centers for 
Disease Control and Prevention (CDC) estimated that from 2010–2011 to 2015–2016, flu-related 
hospitalizations in the United States ranged from a low of 140,000 (during 2011–2012) to a high 
of 710,000 (during 2014–2015) (1). Both the CDC and the United States Advisory Committee on 
Immunization Practices recommend that all individuals 6 months of age and older should receive 
influenza vaccination, which is an effective intervention in reducing transmission. The highest 
priority populations for vaccination are those with disproportionate risk of influenza-associated 
complications, hospitalizations, and death, including children, adults ≥65 years of age, persons with 
chronic medical conditions, and those with an immunocompromised state, including pregnant 
women (2).
We describe the case of a young non-pregnant immunocompetent female with well-controlled 
asthma who presented in spring 2014 with influenza-associated community-acquired pneumonia 
(CAP) secondary to methicillin-resistant Staphylococcus aureus (MRSA) complicated by hypoxic 
respiratory failure, septic shock, and ultimately death.
CLINICaL Case
A 28-year-old female with well-controlled asthma and bipolar disorder presented to the emergency 
department (ED) with 1  day of shortness of breath. She attempted management at home with 
albuterol nebulizer treatments; however, this provoked cough with blood-streaked sputum. The prior 
week, her younger daughter was ill with fever, rhinorrhea, dry cough, and myalgias. The patient 
recalled similar symptoms for 1–2 days; however, they resolved before significant dyspnea ensued. 
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She visited her primary care physician (PCP) 2 months prior for 
a left naris abscess at the site of a nasal ring. A wound culture 
grew MRSA, and she was treated with 7 days of doxycycline with 
clinical improvement. She declined influenza vaccination for the 
2013–2014 season.
On initial presentation to the ED in April 2014, the patient 
had a temperature of 37.1°C, heart rate of 140 beats per minute, 
blood pressure of 114/66, and respiratory rate of 18 breaths per 
minute with an oxygen saturation of 98% on room air. She was 
ill-appearing in mild respiratory distress with left lower lung 
field crackles, tachycardia without murmurs, and bilateral lower 
extremity pitting edema. Laboratory studies revealed pancytope-
nia with a total white blood cell count of 0.9 × 103 cells/μl with 
left shift (58% polymorphonuclear leukocytes, 14% bandemia, 
11% lymphocytes, 13% monocytes), hemoglobin of 11.6 g/dl, and 
platelet count of 110 ×  103  cells/μl. Her chemistry panel dem-
onstrated normal kidney and liver function, with the exception 
of hypoalbuminemia. Urinalysis showed concentration (specific 
gravity of 1.041) with proteinuria and hyaline casts. Qualitative 
urine pregnancy test was negative and serum antibodies against 
human immunodeficiency virus (HIV)-1 and -2 were not detected. 
Chest radiography revealed a homogenous left mid-lung infiltrate 
with possible cavitation (Figure 1A). Electrocardiogram (ECG) 
displayed sinus tachycardia without ST or T wave changes. She 
was started on ceftriaxone and azithromycin for CAP with plan 
for admission.
Her condition then rapidly deteriorated with development of 
fever to 38.5°C, hemodynamic instability (sinus tachycardia to 
160 beats per minute, blood pressure of 82/53), and respiratory 
decompensation (tachypnea of 62 breaths per minute, oxygen 
saturation of 85% on room air, use of accessory muscles, inability 
to speak). She required emergent intubation for hypoxic respira-
tory failure and initiation of vasopressor therapy in addition to 
aggressive fluid resuscitation for septic shock secondary to pneu-
monia. Her antibiotic regimen was broadened to vancomycin, 
piperacillin-tazobactam, azithromycin, and she was admitted to 
the medical intensive care unit.
Given the degree of her shock with significant lactic acido-
sis, she was additionally supported with stress dose steroids, 
transfusion of packed red blood cells, and a bicarbonate infu-
sion. A  computed tomography (CT) angiography of the chest 
though negative for pulmonary embolism revealed extensive 
dense consolidative airspace opacities within both lower lung 
lobes, demonstrating progression from the chest film earlier that 
day and suggestive of a necrotizing process. Clindamycin was 
added for antitoxin effect and doxycycline for possible rickettsial 
infection. Gynecology was consulted to evaluate for pelvic source 
of infection given reported intrauterine device and risk of toxic 
shock syndrome. Given worsening fever to 39.8°C and elevated 
creatine kinase, psychotropic medications for bipolar disorder 
were discontinued, given possibility of neuroleptic malignant 
syndrome.
Extended respiratory viral panels obtained on the day of 
admission by nasopharyngeal swab and bronchoalveolar lavage 
(BAL) were reported on hospital day 2–3 as positive for influenza 
A, subtype H3N2. Additionally, the BAL gram stain and culture 
returned as 4+ Gram-positive cocci in clusters, which speciated 
to MRSA. These new findings prompted urgent initiation of 
oseltamivir, and all other antibiotics were discontinued except 
for vancomycin on hospital day 3. Inability to wean vasopres-
sors prompted investigation of cardiac function which unveiled 
myopericarditis: ECG with diffuse ST elevations and PR depres-
sions most significantly in the late precordial leads to reciprocal 
changes in aVR (Figure 1B) and peak troponin T of 4.07 ng/ml, 
and transthoracic echocardiogram (TTE) disclosed severe global 
left ventricular hypokinesis with an ejection fraction of 25% and 
right ventricular dysfunction.
A number of other complications evolved, including acute renal 
failure, mild hepatitis, worsening pancytopenia, coagulopathy, 
and acute respiratory distress syndrome (ARDS) with develop-
ment of bilateral pleural effusions requiring chest tube placement 
on the left. Despite discontinuation of sedation, her neurologic 
examination remained poor and CT brain obtained on hospital 
day 5 disclosed generalized cerebral edema with decreased dif-
ferentiation of the gray–white matter junction (Figure 1C). Per 
consultation with neurology and neurosurgery, she most likely suf-
fered anoxic brain injury secondary to cardiopulmonary collapse; 
however, influenza encephalitis could not be excluded. Lumbar 
puncture (LP) could not be safely performed, given severe illness 
with clinical instability. An extra-ventricular drain was placed to 
monitor intracranial pressure, hypertonic saline administered, 
and a cooling protocol enacted. Electroencephalogram showed 
diffuse slowing of brain waves 48 h later. A family meeting was 
held and the decision was made to withdraw all life support. She 
expired on hospital day 7.
MetHoDs
Viral RNA was extracted from amplified virus from our patient’s 
BAL specimen in MDCK cells using the QIAamp Viral RNA 
Mini Kit (QIAGEN, Inc., Valencia, CA, USA) and molecularly 
tested using the CDC Real-time RT-PCR (rRT-PCR) protocol for 
detection and characterization of influenza A (matrix), seasonal 
H1, seasonal H3, pandemic H1, H5, and H7. A two-step RT-PCR 
reaction was then performed using the same extracted viral RNA 
and universal primer sets targeting all eight influenza virus gene 
segments (3) and resolved on a 1% agarose gel stained with eth-
idium bromide. Amplified product was purified and submitted to 
a local sequencing company (Eton Bioscience, Inc., Raleigh, NC, 
USA). Sequence data were aligned and edited using BioEdit 7.1.9 
(Ibis Biosciences, Carlsband, CA, USA) and then compared to the 
NCBI sequence database using the BLAST application.
ResULts
Results from the CDC rRT-PCR assay demonstrated that our 
patient’s sample was positive for influenza A (matrix gene) and 
influenza A H3 subtype. Sequencing data from isolated gene 
segments (M, HA, NA, and NS) revealed a 97–98% identity to 
influenza A virus [A/North Carolina/13/2014(H3N2)].
FIGURe 1 | Complications of seasonal influenza a may include (a) secondary bacterial pneumonia as demonstrated by the left mid-lung 
homogenous opacity on chest X-radiography, (B) myopericarditis as shown classically by electrocardiogram with diffuse st elevations and pR 
depressions, and (C) diffuse cerebral edema not excluding viral encephalitis as revealed by computed tomography of the brain.
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DIsCUssIoN
This complex case of seasonal 2013–2014 influenza A, subtype 
H3N2, in a young immunocompetent non-pregnant female is 
unique in many ways. It reminds us that seasonal influenza can 
be deadly, when associated with pre-existing comorbidities and/
or viral-related sequelae, such as bacterial coinfection. Mortality 
among influenza A infections often occurs in children or adults 
≥65  years of age (4), those who are immunocompromised (5) 
and/or associated with bacterial coinfection (6). Associated 
mortality may disproportionately affect younger adults in seasons 
when particular virus types and subtypes are more lethal, such as 
the 2009 H1N1 influenza pandemic (7). Our patient differs from 
the higher risk clinical phenotype for influenza mortality, given 
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her younger age in a non-pandemic season and lack of pregnancy 
or other immunocompromising state (e.g., HIV).
A retrospective study evaluating influenza-associated mor-
bidity and mortality in women aged 15–44 found that in those 
who were considered high-risk—including having chronic lung 
disease—the estimated annual excess was 23 hospitalizations 
and deaths per 10,000 women compared to 4 per 10,000 in those 
without a high-risk condition (8). Comorbid asthma may have 
increased her risk of influenza complications; however, sequelae 
more commonly afflict patients requiring frequent corticosteroid 
use, which may predispose to delayed viral clearance (9) and 
increased susceptibility to bacterial pneumonia (6). Regardless 
of viral infection, asthma and frequent corticosteroid use have 
been identified as independent risk factors for bacterial CAP in 
young adults (10, 11), though the relevance of this in our patient 
is unknown, given she had moderate persistent asthma not 
requiring frequent systemic corticosteroid treatment.
Our patient’s course of H3N2 seasonal influenza A was 
complicated by secondary bacterial MRSA pneumonia result-
ing in hypoxic respiratory failure, septic shock, and ultimately, 
death. Staphylococcus aureus is the second most common 
pathogen after Streptococcus pneumoniae responsible for bac-
terial pneumonia superimposed on influenza infection (12). 
Incidence of S. aureus significantly increases in epidemic years 
(12), and recently, community-acquired MRSA (CA-MRSA) 
has been identified in outbreaks of severe pneumonia with a 
high mortality rate in young, otherwise healthy patients with 
influenza (13, 14). National data of CA-MRSA pneumonia dur-
ing the 2006–2007 influenza season found the median age of 
cases as 16 years, 44% had no known pertinent medical history, 
and 51% died at a median of 4 days after symptom onset (13). 
This underscores the need for health-care providers during 
influenza season to be vigilant for the development of bacterial 
pneumonia in individuals without typical risk factors, such as 
increased age, comorbidities, or immunosuppression. Further, 
empiric CA-MRSA coverage should be considered in young 
adult patients with pneumonia, as this complication of influenza 
may be lethal.
Particularly striking about our patient’s case is the vast 
number of sequelae she developed in the setting of influenza 
coinfection with MRSA pneumonia, including ARDS, empyema, 
myopericarditis, kidney and liver injury, pancytopenia, coagu-
lopathy, and cerebral edema with possible viral encephalitis. The 
pathophysiology of such conditions is most likely attributable to 
her overall degree of critical illness as well as bacterial coinfection 
with MRSA, but is also within the realm of influenza-associated 
morbidity (6, 15–19), especially in non-vaccinated individuals. It 
is not uncommon for pathology secondary to influenza to involve 
the muscle (17) and central nervous system (18), both sites of 
illness typically more common in children. Myopericarditis is a 
more rare complication of influenza (15, 16) and can be fatal, 
especially in the context of influenza B (19), prompting the need 
for early clinical detection as most patients require circulatory 
support and rapid escalation of care. Our patient demonstrated 
strong evidence of myositis and myopericarditis by substantial 
elevation in biomarkers of muscle injury (including those specific 
to the myocardium) and ECG/TTE findings, indicating globally 
decreased myocardial function likely due to inflammation, which 
could be viral-associated. Influenza encephalitis was suspected, 
though could not be confirmed by LP, given her state of critical 
illness.
Our patient declined the opportunity for influenza vaccine 
when evaluated by her PCP 2  months prior to presentation. 
The public health and individual benefits of influenza vaccina-
tion are clear, including promotion of herd immunity (20, 21), 
reduction in influenza-related hospitalizations, and decreased 
severity of illness (22). Additionally, a multicenter case–control 
study of adults and children hospitalized for CAP found patients 
with laboratory-confirmed influenza-associated pneumonia, 
compared with those with pneumonia not associated with influ-
enza, had a lower odds of having received influenza vaccination 
[0.43, 95% confidence interval (CI), 0.28–0.68] (23). Isolation 
of our patient’s virus revealed 97–98% identity to Influenza A 
virus [A/North Carolina/13/2014(H3N2)]. According to data 
analyzed by the CDC, 95.3% of 426 influenza A (H3N2) viruses 
tested were characterized as Texas/50/2012-like, the influenza A 
(H3N2) component of the Northern Hemisphere quadrivalent 
and trivalent vaccines for the 2013–2014 season (24). End of 
the 2013–2014 influenza season estimates for vaccine effective-
ness ranged from 39% (95% CI = −6 to 65%) for persons aged 
≥65  years to 56% (CI =  37–69%) for persons aged 5–19  years 
(25). From October 2013 to May 2014, influenza vaccination 
resulted in an estimated 7.2 million (CI = 5.1–9.9) fewer illnesses, 
3.1 million (CI = 2.1–4.4) fewer medically attended illnesses, and 
90,068 (CI = 51,231–144,571) fewer hospitalizations associated 
with influenza (25). Interestingly, rates of influenza-related hos-
pitalization for adults aged 20–64 were 1.3–5.5 times higher than 
during previous reported seasons (25–27). Taken together, this 
suggests that, had our patient been vaccinated against influenza 
in 2013–2014, her risk of developing laboratory-confirmed viral 
illness could have been reduced by 44–61%; however, likelihood 
of hospitalization may have been less affected, given the younger 
demographic requiring hospitalization in the 2013–2014 seasonal 
influenza.
Last, we query whether our patient’s burden of influenza-
related morbidity and mortality could have been minimized if 
she were diagnosed with influenza earlier and/or empirically 
treated with antiviral therapy. Most studies of neuraminidase 
inhibitors show greatest benefit when therapy is initiated within 
the first 48  h of symptom onset (28). A large meta-analysis of 
randomized controlled trials evaluating oseltamivir compared to 
placebo found treatment of influenza in adults accelerates time 
to clinical symptom alleviation, reduces risk of lower respiratory 
tract complications, and decreases hospitalization (28). In that 
analysis, 838/1565 (53.5%) of patients were given oseltamivir 
>24 h after symptom onset, implying neuraminidase therapy may 
still be beneficial when administered later in the course of illness. 
This is further supported by data for 29,234 patients admitted to 
the hospital with pandemic influenza A H1N1 from 2009 to 2011, 
which found a reduction in mortality risk with neuraminidase 
inhibitor treatment—irrespective of timing—compared with 
no treatment; however, there was an increase in the mortality 
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hazard rate with each day’s delay in therapy initiation up to day 
5 compared to initiation within 2 days of symptom onset (29). In 
our patient’s case, nasopharyngeal- and BAL-sourced respiratory 
viral panels returned positive for influenza A (H3N2) on hospital 
day 2–3 prompting initiation of oseltamivir >48 h after her pres-
entation with fever and dyspnea. Earlier recognition of influenza 
infection and prompt initiation of antiviral therapy may have 
prevented severe illness in this patient who ultimately succumbed 
to numerous complications, including death.
CoNCLUsIoN
Seasonal influenza can be fatal in young, otherwise healthy adults 
with the development of infectious sequelae such as bacterial 
pneumonia. Non-vaccinated individuals are at higher risk of 
influenza-related complications, including bacterial coinfection, 
which may drive clinical decompensation and even death. This 
specific case reminds us that influenza-related MRSA pneumonia 
is not uncommon in young, healthy adults, and early recognition 
of critical illness is crucial in order to promptly initiate more 
comprehensive management, including appropriate antiviral and 
antibiotic therapy, and care escalation as needed.
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